Burkitt’s lymphoma is a rare and aggressive blood cancer characterized by translocation of the MYC gene. It occurs most often in children and young adults. In recent years, CAR-T cell therapy – often referred to as a “survival drug” and administered as a single dose – has been approved for some types of blood cancers, offering hope for a cure even in severe cases. However, its effectiveness against Burkitt lymphoma is limited. Furthermore, developing drugs that directly target MYC, the root cause of this cancer, has proven challenging for decades.
Please follow and like us:
